PF9404C, a new slow NO donor with beta receptor blocking properties

British Journal of Pharmacology

Volumn 128, Issue 8, 1999, Pages 1713-1722

  Villarroya, Mercedes ^a   Herrero, Carlos J ^a   Ruíz Nuño, Ana ^a   De Pascual, Ricardo ^a   Del Valle, Mercedes ^a   Michelena, Pedro ^a   Grau, Manuel ^c   Carrasco, Emilio ^c   López, Manuela G ^a   García, Antonio G ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c Laboratorios Almirall Prodesfarma ^*  (Spain)

Author keywords

Beta blockers; NO donors; PF9404C

Indexed keywords

1 [4 (2,3 DINITROXYPROPOXYMETHYL)PHENOXY] 3 ISOPROPYLAMINO 2 PROPANOL; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; ATENOLOL; BETA ADRENERGIC RECEPTOR; CARVEDILOL; CYCLIC GMP; GLYCERYL TRINITRATE; ISOPRENALINE; ISOSORBIDE DINITRATE; METHYLENE BLUE; METOPROLOL; NITRIC OXIDE; NITRIC OXIDE DONOR; NORADRENALIN; OXYHEMOGLOBIN; PROPRANOLOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA; ARTERY DILATATION; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BRAIN MEMBRANE; CONCENTRATION RESPONSE; DRUG BINDING; DRUG MECHANISM; DRUG POTENCY; GUINEA PIG; HEART LEFT ATRIUM; HEART PROTECTION; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033405856     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702992     Document Type: Article

References (27)

1. ANTÓN, F., CARRASCO, E., GAVALDÁ, A., GRAU, M., MONTERO, J.L., GARCÍA, A.G., PASCUAL, R., LÓPEZ, M.G. & VILLARROYA, M. (1996). PF9104: a novel beta-blocker with coronary and peripheral vasodilatory properties. Meth. Find. Exp. Clin. Pharmacol., 18, 184.
2. BULL, M.A., CARRASCO, E., GRAU, M., MONTERO, J.L., PI, J., PRAT, M., SERRA, X., GARCIA, A.G., DEL VALLE, M. & LOPEZ, M.G. (1995). Síntesis y evaluación farmacológica in vitro de una serie de nitroesteres orgánicos de aril-beta-alcanolaminas con actividad cardiohemodinámica. XVI Jornadas Nacionales de A.E.F.I. Alcalá de Henares, Spain.
3. 50) of an enzymatic reaction. Biochem. Pharmacol., 22, 3099-3108.
4. FEELISCH, M. & NOACK, E. (1987). Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur. J. Pharmacol., 139, 19-30.
5. FURBERG, C.D., PSATY, B.M. & MEYER, J.V. (1995). Dose-related increase in mortality in patients with coronary heart disease. Circulation, 92, 1326-1331.
6. FURCHGOTT, R.F. & ZAWADSZKI, J.V. (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 288, 373-376.
7. GARG, U.C. & HASSID, A. (1989). Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest., 83, 1774-1777.
8. GARTHWAITE, J., SOUTHAM, E., BOULTON, C.L., NIELSEN, E.B., SCHMIDT, K. & MAYER, B. (1995). Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4] o xadiazolo [4,3-a] quinoxalin-1-one. Mol. Pharmacol., 48, 184-188.
9. GRAAF, J.C. DE, BANGA, J.D. MONCADA, S., PALMER R.M.J., DE GROOT, P.G. & SIXMA, J.J. (1992). Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation, 85, 2284-2290.
10. GRUETTER, C.A., GRUETTER, D.Y., LYON, J.E., KADOWITZ, E.J., & IGNARRO, L.J. (1981). Relationship between cyclic guanosine 3′:5′-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceril trinitrate, nitroprusside, nitrate and nitric oxide: effects of methylene blue and methahemoglobin, J. Pharmacol. Exp. Ther., 219, 181-186.
11. IGNARRO, L.J. (1989). Endothelium-derived nitric oxide: actions and properties. FASEB J., 3, 31-36.
12. IGNARRO, L.J., EDWARDS, J.C., GRUETTER, D.Y., BARRY, B.K. & GRUETTER, C.A. (1980). Possible involvement of S-nitrosothiols in the activation of guanylate cyclase by nitroso compounds. FEBS Lett., 110, 275-278.
13. IGNARRO, L.J. & GRUETTER, C.A. (1980). Requirements of thiols for activation of coronary arterial guanylate cyclase by gliceryl trinitrate and sodium nitrate: possible involvements of S-nitrosothiols. Biochim. Biophys. Acta, 631, 221-231.
14. IGNARRO, L.J. & KADOWIZ, P.J. (1985). The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Annu. Rev. Pharmacol. Toxicol., 25, 171-191.
15. LUND-JOHANSEN, P. (1984). Pharmacology of combined alpha-beta blockade. Haemodynamic effects of labetalol. Drugs, 28 (Suppl. 2), 35-50.
16. MA, X.L. & LEFER, A.M. (1993). S-Nitroso-N-acetylpenicillamine is a potent inhibitor of neutrophil-endothelial interaction. Endothelium, 1, 31-39.
17. MCTAVISH, D., CAMPOLI-RICHARDS, D. & SORKIN, E.M. (1993). Carvedilol. A review of its pharmadynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs, 45, 232-258.
18. MIKI, N., KAWABE, Y. & KURIYAMA, K. (1977). Activation of cerebral guanylate cyclase by nitric oxide. Biochem. Biophys. Res. Commun., 75, 851-856.
19. MOILANEN, E., VUORINEN, P., KANKAARERANTA, H., METSAKETELA, T. & VAPPATALO, H. (1992). NO donors inhibit human neutrophil activation in vivo. J. Vasc. Res., 29, 170.
20. MONCADA, S., PALMER, R.J. & HIGGS, E.A. (1991). Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev., 43, 109-163.
21. MORO, M.A., RUSSELL, R.J., CELLER, S., LIZASOAIN, I., SU, Y., DARLEY-USMAR, V.M., RADOMSKI, M.W. & MONCADA, S. (1996). cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using and inhibitor of the soluble guanylyl cyclase. Proc. Natl. Acad. Sci. U.S.A., 93, 1480-1485.
22. MURAD, F., MITTAL, C.K., ARNOLD, W.P., KATSUKI, S. & KIMURA, H. (1978). Guanylate cyclase: activation by azide, nitro compounds, nitric oxide and hydroxyl radical and inhibition by hemoglobin and myoglobin. Adv. Cyclic Nueleotide Res, 9, 145-158.
23. OLSEN, S.L., GILBERT, E.M., RENLUND, D.G., TAYLOR, D.O., YANOWITZ, F.D. & BRISTOW, M.R. (1995). Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J. Am. Coll. Cardiol., 25, 1225-1231.
24. PALMER, R.M.J., FERRIGE, A.G. & MONCADA, S. (1987). Nitric oxide release accounts for the biological activity of endothelium relaxing factor. Nature, 327, 524-526.
25. PSATY, B.M., HECKBERT, S.R., KOEPSELL, T.D., SISCOVICK, D.S. RAGHUNATHAN, T.E., WEISS, N.S. ROSENDAAL, F.R., LEMAITRE, R.N., SMITH, N.L., WAHL, P.W., WAGNER, E.H. & FURBERG, C.D. (1995). The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA, 274, 620-625.
26. STREIN, K. & SPONER, G. (1990). Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and β-adrenoceptor antagonism in a single molecule. Z. Kardiol., 79 (Suppl. 3), 89-98.
27. YUE, T.L. McKENA, P.J. and CHENG, H.Y. (1993). Carvedilol, a new antiypertensive agent, prevents oxidative injury to endothelial cells. Hypertension, 22, 922-928.